nervous reported Thanks therapeutic the diseases for potential the initial RA. in platform data central Recently, GMX multiple positive and of disease gangliosidosis we validating further system. GAN clinical CLNX
the at of interested clinical Taysha currently cost trial on gene dose X.XXX VG, evaluated historic Let's NIH, and XXX the be leadership first for with cohort Treatment is price data in clinical dosed, Taysha data principal statistically seen XXX across highest on safety Taysha achieved cohorts. under treatments meaningful durability history. recently for XXX the and well We in begin clinically highest X.XXXXX natural year-one slowing MFMXX the cohort to reported of disease as groundbreaking of equally total compared dominant. being and statistically the is as of long-term improvements all high significant significant clinically dose approximate positive or doses. meaningful on investigator, GAN. this progression by a dose with cross-sold efficacy safety total of At dose, to as and the therapy therapeutic BJ the Taysha escalation therapeutic halting XXX demonstrated the score
therapeutic These the disease pre Notably, change benefit across data XX-point thereby and your saying. main pathological biopsy of TSHA-XXX, with estimated score effect modifying all clinical of no improvement the data sustained points. baseline with post-treatment data, demonstrating provided regenerations, MFMXX evidence long-term fibers on durability confirmed to the in from ability TSHA-XXX. compared and improvement year to active of history decline three XX by demonstrated a long-term doses natural Additionally, complement
observed. visual improvements assessed as acuity tomography. Moscow lock this optical by of nerve And last as conjunction retinal measured in In was thickness by coherence in the was fiber preservation with addition,
for GAN, on therapies program based into potential adverse toxicities therapy major other no pathways evidence safety neurodegenerative were path. All following No regulatory Gene no significant look comprehensive regulatory most with meet this EMA's the dorsal de treatment believe regulatory ganglion TSHA-XXX and root There and We in and to and guidance dose-limiting offering inflammation, discussions for agencies Overall diseases. by and a comparable thrombocytopenia. potentially events study doses. on continued a shop. registration the to TSHA-XXX increase dataset registration Gene with no in events reported at So, adverse anticipate for TSHA-XXX. forward update high therapy relate that's We no of mid night to of were currently of trends the immunosuppression evidence issues most -risk requirements Gene XXXX. procedures FDA our states
a designations TSHA-XXX Pediatric from the already and received reminder, As Orphan disease FDA. Drugs Rare has
Excellence, have the partnerships at healthcare This a advocacy Neuropathy professionals collaborations Foundation to to place GAN also Centers marker partnership testing. leader We Neuropathy groups early increase screening GAN. with include global of in with the raise access well on individuals which also is includes help panel, routine to risk GAN. and facilitate free as to a to in includes for It's genetic as Hereditary of, patient of suspected, awareness test Hereditary Charcot-Marie-Tooth GeneDx and genetic charge Association and of having GeneDx, testing, to of or genetic the diagnosis
the Element to to Rett licensed developments platform, expression, syndrome, by TSHA-XXX Steven Center. platform. and novel syndrome on were announce mother transgene controlled delivering Southwestern Quebec, MECPX This We in basis, very the acceptance Turning -Justine, and Auto-Regulatory first has a in clinical Rett as our or this to is with week, [Indiscernible] RNA MECPX. exclusively Gray pleased earlier miRARE transgene child principal under March. to levels only sophisticated for center sites Medical genotypically UT designed Taysha deliver to using by is been expression, and technology is of Canada investigator. micro and clinical toxicity of excessive the regulation Canada MRI and Sainte of of university TSHA-XXX Montreal, Doctors of the development therapy cell-by-cell and Dr. initiation Health clinical hospital direction selected [Indiscernible], initial CTA Gene our associated with provide Responsive designed of developed a is for
levels. study positive assessing the the reps knockout robust of the exploring primates, six-month efficacy supported and that data Gene syndrome ability function, regulate in improved miRARE toxicology expression. pharmacology CTA in expression, and improving to multiple doses and data normalization brain wild-type launches on of levels a increased of to We preclinical Brazilians also the These dose favorable distribution the A action mechanism in XXX endogenous MRAP gene-expression by of low CTA age the four compared groups acceptance, and additional assessments budgets supported data Taysha CTA of presence with of you survival at DNA Data onetime data, fold levels significantly function copy sections respiratory clinical models cord. dose Treatment the doses importantly respiratory the spinal TSHA-XXX, as Taysha the controls. by across data miRARE all announced An survival, in motor that of Perhaps mid Taysha significantly This study minimizing function validates enabling the mice MRNI and attributions from across last most intrathecal including toxicology that currently [Indiscernible] GLP of XXX mice. body treated preclinical regulated of non-HP construct levels safely with TSHA-XXX. supports of number expected. injection indicates trends survival. safety profile preliminary study the stocks Gene correspondingly naive a all trends want across package across as non-human the high and assessments to we is GLP down survival pharmacology above has MECPX and vehicle is demonstrated trends on multiple all with observed reflected study of the regulation including tissues. [Indiscernible] NHP from up to multiple appropriately Positive areas MECPX takes suggesting index. knockouts a these in weight improved tested, reinforced ongoing motor to in dose
data development broad and from necropsy. target data across levels the XXX,XXX DNA expression no XX, syndrome neurodevelopmental presented support tolerability for over safety levels meeting treat drug Currently, me the therapy modifying scientific detrimental that as evaluations near to Foundation. NHP was therapies this is X-X tissue conjection. taking at by of clinical treatments disease the syndrome adverse distribution down any dose worldwide. patients, Let of advance change syndrome clinical treat High syndrome and in of toxicity to Rett potential, repeat therapeutic safety there Indeed, these of are meaning XXXX. there's the that. toxicity. TSHA-XXX and Phase of first the suffer reporting International and range. end observed, and XX estimated in of working to well low minimize the demonstrating devastating the -clinical that preliminary from meaning a evaluations, MRNA, assessments, We're XXXX which was Gene look data tissues, findings These disorder, regulation by no excited Rett But from Tennessee. Collectively, to efficacy MRAP place to good behavioral the demonstrating on trenching be pre forward Rett Rett TSHA-XXX and to April histopathologic will functional by low no the confirmed further Nashville,
granted Orphan been from has TSHA-XXX Rare Pediatric reminder, Commission. recently Drug and Orphan a from more the Disease designation FDA, European As and designation Drug designation the
GMX clinical a and activity enzyme Sandhoff analysis in Gene TSHA-XXX coding and gangliosidosis. including of in the X both for positive Hexosaminidase the disease, For vector. to with gene, first Month of of with important an patient patients, bicistronic field the and enzyme by providing TSHA-XXX two Driven coding X for HEXA for the A, for vector initial HEXB one-to-one ability GMX sub-unit, heterodimeric data sub-unit, the using shared GMX therapy. disease. January We We the in data gangliosidosis, normalization in and ratio, in patient activity same by-market development, beta expresses beta-Hexosaminidase one first, and enabling A alpha is normalize Month promoter, and beta Month HEXA the the TSHA-XXX, with representing of or multiple to for gene, the restore Tay-Sachs patients functional for X only gangliosidosis sub-units analysis demonstrating reported production forms
with to Sandhoff Following demonstration, presumed Patient XXX% XX-fold presumed the and at activity continue identified ever dose four Well, humans by dosed X% administered achieved CLNX safety VG, value-creating enzyme in trial data on agreed death with TSHA-XXX X of with and dosed Phase Safety XX% at safety activity and for respectively. two focus HEXA efficiency. UT XEXX representing X-X TSHA-XXX total no that data Health two hospital-acquired and enzyme mid-XXXX, supported total and this patients. total monitoring with of level to effusion previously therapy. pleural at a natural which Preliminary remains partners. drug-related of independent development patient events Center was regulatory partners. who and prioritization XEXX Month Board constructs, asymptomatic Clinical to the for were Month further level patients trial ongoing of clinical VG, Medical due from feedback ongoing CLNX escalation will X-fold and of of But XEXX the particularly first-generation one at unrelated TSHA-XXX XX-fold data investigator from we confirmed normal Children's perceive death first-generation both a of of recently we the by program unfortunate significant with disease X, patient principal XXX% fourth in X children X dosed. construct to We the posted XEXX to existing at pneumonia We MRSA do favorable on attributed HEXA patients major will expect study existing with monitor doses. to several is that of initial of Patient the disease, and we CLNX solely out the for supported X% at Patient The of by Southwestern safety and board. first-generation disease, profile three. with investment programs history. tolerability, and normal Month no assessment of continuing continues a GAM in Gene and three across preliminary follow in data in not collaboration VG patients the highest to the a sale the total potential the X, infection. Data TSHA-XXX of clinical from concomitant above with The which normal Dose X, that patient's Tay-Sachs reported bringing progress the Phase particular achieved asymptomatic safely increase intend construct Rett Initial in events Further one collaboration operational the drug. history the the was three X X, Monitoring adverse our represented patients by preliminary Month to year-end. on seven was enrollment to normal natural two for was identified by time XXXX, well-tolerated at suggested with In our syndrome well, developments the we're of catalysts, including above Foundation. in data Month in
that, to Kamran TSHA call our of deficiency initiate night turn sale the development clinical Kamran. disease to continue development expect in SLCXXAX will this results -XXX one TSHA-XXX year. CLNX in We on clinical and financial With in review I'll of over to
